查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1178057

罕见肾臟疾病治疗市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2022年～2031年)

Rare Kidney Diseases Treatment Market (Drug Class: Enzyme Replacement Therapy, Monoclonal Antibodies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 186 Pages | 商品交期: 2-10个工作天内

价格

本报告提供全球罕见肾臟疾病治疗市场相关调查，提供市场概要，以及2022年～2031年的预测，各适应症，各类药物，各流通管道，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 前提与调查手法

第3章 摘要整理:全球罕见肾臟疾病治疗市场

第4章 市场概要

  • 简介
  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 全球罕见肾臟疾病治疗市场分析与预测，2017年～2031年

第5章 主要洞察

第6章 全球罕见肾臟疾病治疗市场分析与预测，各适应症

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测，各适应症，2017年～2031年
    • 法布瑞氏症
    • 非典型溶血性尿毒症症候群
    • 狼疮性肾炎
    • 肾臟病性胱胺酸症
    • 其他
  • 市场魅力分析，各适应症

第7章 全球罕见肾臟疾病治疗市场分析与预测，各类药物

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测，各类药物，2017年～2031年
    • 酵素补充疗法
    • 单株抗体
    • 其他
  • 市场魅力分析，各类药物

第8章 全球罕见肾臟疾病治疗市场分析与预测，各流通管道

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测，各流通管道，2017年～2031年
    • 医院药局
    • 零售药局
    • 线上销售
  • 市场魅力分析，各流通管道

第9章 全球罕见肾臟疾病治疗市场分析与预测，各地区

  • 主要调查结果
  • 市场价值预测，各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲
  • 市场魅力分析，各地区

第10章 北美的罕见肾臟疾病治疗市场分析与预测

第11章 欧洲的罕见肾臟疾病治疗市场分析与预测

第12章 亚太地区的罕见肾臟疾病治疗市场分析与预测

第13章 南美的罕见肾臟疾病治疗市场分析与预测

第14章 中东·非洲的罕见肾臟疾病治疗市场分析与预测

第15章 竞争情形

  • 市场参与企业-竞争矩阵(各等级及各企业规模)
  • 市场占有率分析，各企业，2021年
  • 企业简介
    • Calliditas Therapeutics AB
    • GSK plc
    • Aurinia Pharmaceuticals, Inc.
    • Amicus Therapeutics, Inc.
    • Shire(Takeda Pharmaceutical Company Limited)
    • Sanofi
    • Advicenne
    • Alexion Pharmaceuticals, Inc.
    • Horizon Therapeutics plc
    • Otsuka Pharmaceutical Co., Ltd.
    • Reata Pharmaceuticals, Inc.
Product Code: TMRGL85247

TMR's report on the global rare kidney diseases treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global rare kidney diseases treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global rare kidney diseases treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the rare kidney diseases treatment market.

The report delves into the competitive landscape of the global rare kidney diseases treatment market. Key players operating in the global rare kidney diseases treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global rare kidney diseases treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Rare Kidney Diseases Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Disease Epidemiology
  • 5.3. Key Industry Events
  • 5.4. COVID-19 Impact Analysis

6. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Indication

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Indication, 2017-2031
    • 6.3.1. Fabry Disease
    • 6.3.2. Atypical Hemolytic Uremic Syndrome
    • 6.3.3. Lupus Nephritis
    • 6.3.4. Nephropathic Cystinosis
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Indication

7. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Drug Class, 2017-2031
    • 7.3.1. Enzyme Replacement Therapy
    • 7.3.2. Monoclonal Antibodies
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Drug Class

8. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Sales
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Rare Kidney Diseases Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Indication, 2017-2031
    • 10.2.1. Fabry Disease
    • 10.2.2. Atypical Hemolytic Uremic Syndrome
    • 10.2.3. Lupus Nephritis
    • 10.2.4. Nephropathic Cystinosis
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Drug Class, 2017-2031
    • 10.3.1. Enzyme Replacement Therapy
    • 10.3.2. Monoclonal Antibodies
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Sales
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Indication
    • 10.6.2. By Drug Class
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Rare Kidney Diseases Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Indication, 2017-2031
    • 11.2.1. Fabry Disease
    • 11.2.2. Atypical Hemolytic Uremic Syndrome
    • 11.2.3. Lupus Nephritis
    • 11.2.4. Nephropathic Cystinosis
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Drug Class, 2017-2031
    • 11.3.1. Enzyme Replacement Therapy
    • 11.3.2. Monoclonal Antibodies
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Sales
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Indication
    • 11.6.2. By Drug Class
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Rare Kidney Diseases Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Indication, 2017-2031
    • 12.2.1. Fabry Disease
    • 12.2.2. Atypical Hemolytic Uremic Syndrome
    • 12.2.3. Lupus Nephritis
    • 12.2.4. Nephropathic Cystinosis
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Drug Class, 2017-2031
    • 12.3.1. Enzyme Replacement Therapy
    • 12.3.2. Monoclonal Antibodies
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Sales
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Indication
    • 12.6.2. By Drug Class
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Rare Kidney Diseases Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Indication, 2017-2031
    • 13.2.1. Fabry Disease
    • 13.2.2. Atypical Hemolytic Uremic Syndrome
    • 13.2.3. Lupus Nephritis
    • 13.2.4. Nephropathic Cystinosis
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Drug Class, 2017-2031
    • 13.3.1. Enzyme Replacement Therapy
    • 13.3.2. Monoclonal Antibodies
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Sales
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Indication
    • 13.6.2. By Drug Class
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Rare Kidney Diseases Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Indication, 2017-2031
    • 14.2.1. Fabry Disease
    • 14.2.2. Atypical Hemolytic Uremic Syndrome
    • 14.2.3. Lupus Nephritis
    • 14.2.4. Nephropathic Cystinosis
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Drug Class, 2017-2031
    • 14.3.1. Enzyme Replacement Therapy
    • 14.3.2. Monoclonal Antibodies
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Sales
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Indication
    • 14.6.2. By Drug Class
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Calliditas Therapeutics AB
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Overview
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. Strategy Overview
      • 15.3.1.5. SWOT Analysis
    • 15.3.2. GSK plc
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Overview
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. Strategy Overview
      • 15.3.2.5. SWOT Analysis
    • 15.3.3. Aurinia Pharmaceuticals, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Overview
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. Strategy Overview
      • 15.3.3.5. SWOT Analysis
    • 15.3.4. Amicus Therapeutics, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Overview
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. Strategy Overview
      • 15.3.4.5. SWOT Analysis
    • 15.3.5. Shire (Takeda Pharmaceutical Company Limited)
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Overview
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. Strategy Overview
      • 15.3.5.5. SWOT Analysis
    • 15.3.6. Sanofi
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Overview
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. Strategy Overview
      • 15.3.6.5. SWOT Analysis
    • 15.3.7. Advicenne
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Overview
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. Strategy Overview
      • 15.3.7.5. SWOT Analysis
    • 15.3.8. Alexion Pharmaceuticals, Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Overview
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. Strategy Overview
      • 15.3.8.5. SWOT Analysis
    • 15.3.9. Horizon Therapeutics plc
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Overview
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. Strategy Overview
      • 15.3.9.5. SWOT Analysis
    • 15.3.10. Otsuka Pharmaceutical Co., Ltd.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Overview
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. Strategy Overview
      • 15.3.10.5. SWOT Analysis
    • 15.3.11. Reata Pharmaceuticals, Inc.
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Overview
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. Strategy Overview
      • 15.3.11.5. SWOT Analysis

List of Tables

  • Table 01: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 02: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 07: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 08: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 11: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 16: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country/Sun-region, 2017-2031
  • Table 18: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 19: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country/Sun-region, 2017-2031
  • Table 22: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 23: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 24: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 25: Business Overview (Calliditas Therapeutics AB)
  • Table 26: Business Overview (GSK plc)
  • Table 27: Business Overview (Aurinia Pharmaceuticals, Inc.)
  • Table 28: Business Overview (Amicus Therapeutics, Inc.)
  • Table 29: Business Overview (Shire (Takeda Pharmaceutical Company Limited)
  • Table 30: Business Overview (Sanofi)
  • Table 31: Business Overview (Advicenne)
  • Table 32: Business Overview (Alexion Pharmaceuticals, Inc.)
  • Table 33: Business Overview (Horizon Therapeutics plc)
  • Table 34: Business Overview (Otsuka Pharmaceutical Co., Ltd.)
  • Table 35: Business Overview (Reata Pharmaceuticals, Inc.)

List of Figures

  • Figure 01: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Rare Kidney Diseases Treatment Market Value Share, by Indication (2021)
  • Figure 03: Global Rare Kidney Diseases Treatment Market Value Share, by Drug Class (2021)
  • Figure 04: Global Rare Kidney Diseases Treatment Market Value Share, by Distribution Channel (2021)
  • Figure 05: Global Rare Kidney Diseases Treatment Market Value Share, by Region (2021)
  • Figure 06: Global Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 07: Global Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 08: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Fabry Disease, 2017-2031
  • Figure 09: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Atypical Hemolytic Uremic Syndrome, 2017-2031
  • Figure 10: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Lupus Nephritis, 2017-2031
  • Figure 11: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Nephropathic Cystinosis, 2017-2031
  • Figure 12: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 13: Global Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 14: Global Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 15: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Enzyme Replacement Therapy, 2017-2031
  • Figure 16: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Monoclonal Antibodies, 2017-2031
  • Figure 17: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 18: Global Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 19: Global Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 20: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 21: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 22: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 23: Global Rare Kidney Diseases Treatment Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 24: Global Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 25: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 26: North America Rare Kidney Diseases Treatment Market Value Share (%), by Country, 2021 and 2031
  • Figure 27: North America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 28: North America Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 29: North America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 30: North America Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 31: North America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 32: North America Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 33: North America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 34: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 35: Europe Rare Kidney Diseases Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 36: Europe Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 37: Europe Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 38: Europe Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 39: Europe Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 40: Europe Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 41: Europe Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 42: Europe Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 43: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 44: Asia Pacific Rare Kidney Diseases Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 45: Asia Pacific Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 46: Asia Pacific Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 47: Asia Pacific Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 48: Asia Pacific Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 49: Asia Pacific Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 50: Asia Pacific Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 51: Asia Pacific Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 52: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 53: Latin America Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 54: Latin America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 55: Latin America Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 56: Latin America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 57: Latin America Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 58: Latin America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 59: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 60: Middle east and Africa Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 61: Middle east and Africa Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 62: Middle east and Africa Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 63: Middle east and Africa Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 64: Middle east and Africa Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 65: Middle east and Africa Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 66: Global Rare Kidney Diseases Treatment Market Share, by Company, 2021